BRPI0506679A - métodos de tratar osteoartrite com antagonistas de il-6 - Google Patents

métodos de tratar osteoartrite com antagonistas de il-6

Info

Publication number
BRPI0506679A
BRPI0506679A BRPI0506679-4A BRPI0506679A BRPI0506679A BR PI0506679 A BRPI0506679 A BR PI0506679A BR PI0506679 A BRPI0506679 A BR PI0506679A BR PI0506679 A BRPI0506679 A BR PI0506679A
Authority
BR
Brazil
Prior art keywords
antagonists
methods
treating osteoarthritis
osteoarthritis
treating
Prior art date
Application number
BRPI0506679-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Elizabeth Bove
Kenneth Stanley Kilgore
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0506679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0506679A publication Critical patent/BRPI0506679A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0506679-4A 2004-02-11 2005-01-31 métodos de tratar osteoartrite com antagonistas de il-6 BRPI0506679A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54381404P 2004-02-11 2004-02-11
PCT/IB2005/000240 WO2005080429A2 (en) 2004-02-11 2005-01-31 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies

Publications (1)

Publication Number Publication Date
BRPI0506679A true BRPI0506679A (pt) 2007-05-15

Family

ID=34885980

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506679-4A BRPI0506679A (pt) 2004-02-11 2005-01-31 métodos de tratar osteoartrite com antagonistas de il-6

Country Status (9)

Country Link
US (2) US20080145367A1 (cg-RX-API-DMAC10.html)
EP (1) EP1715891B2 (cg-RX-API-DMAC10.html)
JP (1) JP2008505054A (cg-RX-API-DMAC10.html)
AT (1) ATE464908T1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0506679A (cg-RX-API-DMAC10.html)
CA (1) CA2555688C (cg-RX-API-DMAC10.html)
DE (1) DE602005020743D1 (cg-RX-API-DMAC10.html)
ES (1) ES2341461T5 (cg-RX-API-DMAC10.html)
WO (1) WO2005080429A2 (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
WO2008019061A2 (en) 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
RU2565809C2 (ru) * 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
RU2563830C2 (ru) * 2011-02-08 2015-09-20 Эббви Инк. Лечение остеоартрита и боли
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2016044153A1 (en) * 2014-09-18 2016-03-24 Rush University Medical Center Methods for preventing or treating osteoarthritis
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
AU2016302768B2 (en) 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT52962A (en) * 1988-03-04 1990-09-28 Sandoz Ag Process for production of medical compositions eliminating bone-absorption and promoting forming of bones
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU700819B2 (en) * 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
US5617790A (en) * 1995-05-31 1997-04-08 P.R. Graphics Limited Apparatus for producing flexographic printing plates
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos

Also Published As

Publication number Publication date
WO2005080429A3 (en) 2006-02-23
CA2555688A1 (en) 2005-09-01
EP1715891A2 (en) 2006-11-02
US20100215654A1 (en) 2010-08-26
ES2341461T3 (es) 2010-06-21
DE602005020743D1 (de) 2010-06-02
EP1715891B2 (en) 2014-08-13
US20080145367A1 (en) 2008-06-19
JP2008505054A (ja) 2008-02-21
WO2005080429A2 (en) 2005-09-01
ES2341461T5 (es) 2014-10-29
ATE464908T1 (de) 2010-05-15
CA2555688C (en) 2011-11-08
EP1715891B1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
DE602005020743D1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
NL301145I2 (nl) Tirbanibulin
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA200870409A1 (ru) Антагонисты киназы pi3
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
TW200732349A (en) Anti-OX40L antibodies and methods using same
EA200802168A1 (ru) Гуманизированное антитело к с-kit
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
ATE499138T1 (de) Implantierbare vorrichtung
ATE489368T1 (de) Pyrimidinonverbindungen als calcilytica
DK1835912T3 (da) Substituerede benzimidazoler til behandling af histomoniasis
EA200501137A1 (ru) Способ и промежуточные соединения для получения оланзапина
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.